DGAT1 and fatty liver disease: The beneficial metabolic effects of Compound B may, at least partly, be ascribed to suppressed fat absorption from the intestine via inhibited intestinal DGAT1, as postprandial hyperlipidemia is assumed to promote hepatic steatosis [16] and insulin resistance.